Direction audit: the gain line described the method, not an outcome; restated as the finding; the problem line described the method, not an outcome; restated as the finding.
The exact text we saved
This is the version exactly as it was saved, character for character. The SHA-256 hash below is a 64-character code worked out from that text. Run the same text through SHA-256 and you get the same code; change a single letter and the code comes out completely different. Each version also stores the previous version’s hash, which chains them together so no version can be swapped out quietly.
TRUVACE RECORD VERSION record: TRV-2026-1233 version: 2 kind: revised reason: Direction audit: the gain line described the method, not an outcome; restated as the finding; the problem line described the method, not an outcome; restated as the finding. timestamp: 2026-10-26T06:38:37.904025Z status: published lens: trace sector: health headline: Incremental Propensity Score Interventions: A Primer for Pharmacoepidemiologists dek: Background In observational pharmacoepidemiology, estimating average treatment effects (ATEs) is often challenging due to a lack of practical positivity. In highly selective clinical settings, certain patients almost always or never receive treatment, causing ATE estimators to rely on unstable extrapolation. Incremental propensity score interventions (IPSIs) offer a stochastic alternative by shifting each patient's probability of treatment, providing a more clinically realistic framework that circumvents positiv… gain_title: The study illustrates incremental propensity score interventions as a more clinically realistic method for evaluating abciximab effects; the summary states no mortality reduction result. problem_title: Standard ATE estimates in highly selective PCI settings rely on unrealistic treatment assignment assumptions, which the IPSI approach avoids. trace_subject: effect of abciximab treatment assignment on 6-month mortality in 996 patients undergoing PCI gain_reading: The study illustrates incremental propensity score interventions as a more clinically realistic method for evaluating abciximab effects; the summary states no mortality reduction result. gain_evidence: shifting each patient's probability of receiving abciximab by a predetermined amount on six-month mortality | 6-month mortality would be significantly reduced under a strong treatment policy promoting abciximab administration problem_reading: Standard ATE estimates in highly selective PCI settings rely on unrealistic treatment assignment assumptions, which the IPSI approach avoids. problem_evidence: estimating average treatment effects (ATEs) is often challenging due to a lack of practical positivity | certain patients almost always or never receive treatment, causing ATE estimators to rely on unstable extrapolation | practical interpretability of the ATE estimate may be limited because it implicitly assumes that patients with a near-certain probability of treatment could realistically be assigned to withhold abciximab quick_read: Researchers illustrated incremental propensity score interventions using 996 patients undergoing percutaneous coronary intervention, estimating propensity scores and outcomes with a Super Learner ensemble and 10-fold splitting to evaluate shifting each patient's probability of receiving abciximab on six-month mortality. The work matters because standard ATE estimates in this highly selective setting rely on unrealistic assignment assumptions, while IPSIs offer a clinically realistic stochastic alternative; uncertainty remains about generalizability beyond this single PCI cohort and about optimal shift magnitude for policy implementation. limitation: tag: Dual reading key_points: Analysis used observational data from a cohort of 996 patients undergoing percutaneous coronary intervention (PCI). | Propensity scores and outcome predictions were estimated using a machine learning ensemble (Super Learner) with 10-fold sample splitting. | ATE estimate was risk difference = -0.059, 95% CI: -0.104 to -0.015 for abciximab vs PCI alone. | IPSIs evaluated by shifting treatment propensity by odds ratios ranging from 0.1 to 10. rundown: The study applied incremental propensity score interventions to 996 PCI patients to avoid strict positivity requirements, estimating effects across odds ratio shifts from 0.1 to 10 rather than forcing all patients into treated vs untreated counterfactuals. Propensity and outcome models were fit with Super Learner and 10-fold sample splitting, yielding an ATE risk difference of -0.059 for abciximab, while IPSI results supported mortality reduction under policies that increase treatment propensity. sources: - peer_reviewed | Pharmacoepidemiology and Drug Safety | https://doi.org/10.1002/pds.70484 | 2026-10-01 prev: 9bbf46ade60d29348c150cfdd994f2141287be530b50558dc89dd7510941b744
- SHA-256 hash
- ffd054920763e526e22689fe1644621898819d2f733cef3d8dba74392bbdf2f8
- Previous version’s hash
- 9bbf46ade60d29348c150cfdd994f2141287be530b50558dc89dd7510941b744
How to check it yourself, without trusting this page
Download any version from /api/record/TRV-2026-1233 and hash its canonical field yourself, for example with shasum -a 256. You should get its content_hash. Each version’s text also ends with prev:and the hash of the version before it (version 1 points to 64 zeros). If anyone had changed a single character of any version after it was saved, those hashes wouldn’t line up.
ace